CREB3L2-PPARγ fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis

Cancer Research

Volumn 68, Issue 17, 2008, Pages 7156-7164

  Lui, Weng Onn ^b   Zeng, Lingchun ^a   Rehrmann, Victoria ^a   Deshpande, Seema ^c   Tretiakova, Maria ^a   Kaplan, Edwin L ^a   Leibiger, Ingo ^b   Leibiger, Barbara ^b   Enberg, Ulla ^b   Höög, Anders ^b   Larsson, Catharina ^b   Kroll, Todd G ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HOMEODOMAIN PROTEIN; HYBRID PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN CREB3L2; PROTEIN EVX1; THYROGLOBULIN; THYROTROPIN; UNCLASSIFIED DRUG; CREB3L2 PROTEIN, HUMAN; PRIMER DNA;

ARTICLE; CELL PROLIFERATION; CHROMOSOME REARRANGEMENT; CONTROLLED STUDY; GENE FUSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID FOLLICULAR CARCINOMA; CELL MEMBRANE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC TRANSCRIPTION; GENETICS; HYDROLYSIS; METABOLISM; MOLECULAR GENETICS; MUTATION; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID TUMOR;

BASE SEQUENCE; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL MEMBRANE; CELL PROLIFERATION; DNA PRIMERS; HUMANS; HYDROLYSIS; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR SEQUENCE DATA; MUTATION; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 52049095050     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1085     Document Type: Article

References (55)

1. Mitelman F, Johansson B, Mertens F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat Genet 2004;36:331-4.
2. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
3. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
4. Heilman SA, Kuo YH, Goudswaard CS, et al. Cbfγ reduces Cbfγ-SMMHC-associated acute myeloid leukemia in mice. Cancer Res 2006;66:11214-8.
5. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins. Proc Natl Acad Sci U S A 2000;97:10173-8.
6. Licht JD. Reconstructing a disease: what essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia? Cancer Cell 2006;9:73-4.
7. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994;79:1147-56.
8. Rosen ED, Sarraf P, Troy AE, et al. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999;4:611-7.
9. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999;402:880-3.
10. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor γ (PPARγ). J Biol Chem 1995;270:12953-6.
11. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998;391:79-82.
12. Nagy L, Tontonoz P, Alvarez JG, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 1998;93:229-40.
13. Zhang J, Fu M, Cui T, et al. Selective disruption of PPARγ 2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci U S A 2004;101:10703-8.
14. Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPARγ associated with human colon cancer. Mol Cell 1999;3:799-804.
15. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000;289:1357-60.
16. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-11.
17. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1998;1:465-70.
18. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998;4:1046-52.
19. Martelli ML, Iuliano R, Le Pera I, et al. Inhibitory effects of peroxisome proliferator-activated receptor γ on thyroid carcinoma cell growth. J Clin Endocrinol Metab 2002;87:4728-35.
20. Palakurthi SS, Aktas H, Grubissich LM, et al. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res 2001;61:6213-8.
21. Saez E, Rosenfeld J, Livolsi A, et al. PPARγ signaling exacerbates mammary gland tumor development. Genes Dev 2004;18:528-40.
22. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 1998;4:1058-61.
23. Girnun GD, Smith WM, Drori S, et al. APC-dependent suppression of colon carcinogenesis by PPARγ. Proc Natl Acad Sci U S A 2002;99:13771-6.
24. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998;4:1053-7.
25. Wolfe MS, Kopan R. Intramembrane proteolysis: theme and variations. Science 2004;305:1119-23.
26. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006;124:35-46.
27. Kondo S, Saito A, Hino S, et al. BBF2H7, a novel transmembrane bZIP transcription factor, is a new type of endoplasmic reticulum stress transducer. Mol Cell Biol 2007;27:1716-29.
28. Stirling J, O'Hare P. CREB4, a transmembrane bZip transcription factor and potential new substrate for regulation and cleavage by S1P. Mol Biol Cell 2006;17:413-26.
29. Storlazzi CT, Mertens F, Nascimento A, et al. Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. Hum Mol Genet 2003;12:2349-58.
30. Mertens F, Fletcher CD, Antonescu CR, et al. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest 2005;85:408-15.
31. DeLellis R, Lloyd R, Heitz P, et al., editors. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004.
32. Lui WO, Kytola S, Anfalk L, et al. Balanced translocation t(3;7)(p25;q34): another mechanism of tumorigenesis in follicular thyroid carcinoma? Cancer Genet Cytogenet 2000;119:109-12.
33. Williams DW, Wynford-Thomas D. Human thyroid epithelial cells. Methods Mol Biol 1997;75:163-72.
34. French CA, Alexander EK, Cibas ES, et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 2003;162:1053-60.
35. Lui WO, Foukakis T, Liden J, et al. Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR(γ) fusion oncogene. Oncogene 2005;24:1467-76.
36. Farnebo F, Enberg U, Grimelius L, et al. Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism. J Clin Endocrinol Metab 1997;82:3481-6.
37. Conkright MD, Guzman E, Flechner L, et al. Genome-wide analysis of CREB target genes reveals a core promoter requirement for cAMP responsiveness. Mol Cell 2003;11:1101-8.
38. DeBose-Boyd RA, Brown MS, Li WP, et al. Transport-dependent proteolysis of SREBP: relocation of site-1 protease from Golgi to ER obviates the need for SREBP transport to Golgi. Cell 1999;99:703-12.
39. Lippincott-Schwartz J, Yuan L, Tipper C, et al. Brefeldin A's effects on endosomes, lysosomes, and the TGN suggest a general mechanism for regulating organelle structure and membrane traffic. Cell 1991;67:601-16.
40. Lippincott-Schwartz J, Yuan LC, Bonifacino JS, et al. Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER. Cell 1989;56:801-13.
41. Krause KH, Michalak M. Calreticulin. Cell 1997;88:439-43.
42. Shankar DB, Cheng JC, Kinjo K, et al. The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. Cancer Cell 2005;7:351-62.
43. Coxon A, Rozenblum E, Park YS, et al. Mect1-2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. Cancer Res 2005;65:7137-44.
44. Dwight T, Thoppe SR, Foukakis T, et al. Involvement of the PAX8/peroxisome proliferator-activated receptor γ rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 2003;88:4440-5.
45. Nikiforova MN, Biddinger PW, Caudill CM, et al. PAX8-PPARγ rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 2002;26:1016-23.
46. Shirokawa JM, Elisei R, Knauf JA, et al. Conditional apoptosis induced by oncogenic ras in thyroid cells. Mol Endocrinol 2000;14:1725-38.
47. Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
48. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005;65:4238-45.
49. Basolo F, Giannini R, Monaco C, et al. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am J Pathol 2002;160:247-54.
50. Zhang K, Shen X, Wu J, et al. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell 2006;124:587-99.
51. DenBoer LM, Hardy-Smith PW, Hogan MR, et al. Luman is capable of binding and activating transcription from the unfolded protein response element. Biochem Biophys Res Commun 2005;331:113-9.
52. Denoyelle C, Abou-Rjaily G, Bezrookove V, et al. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 2006;8:1053-63.
53. Moenner M, Pluquet O, Bouchecareilh M, et al. Integrated endoplasmic reticulum stress responses in cancer. Cancer Res 2007;67:10631-4.
54. Kimura T, Van Keymeulen A, Golstein J, et al. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 2001;22:631-56.
55. van Staveren WC, Solis DW, Delys L, et al. Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. Proc Natl Acad Sci U S A 2006;103:413-8.